CASI Pharmaceuticals Inc
CASI0.925USD
-0.025-2.66%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
14.33MMarket Cap
LossP/E TTM
More Details of CASI Pharmaceuticals Inc Company
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
CASI Pharmaceuticals Inc Info
Ticker SymbolCASI
Company nameCASI Pharmaceuticals Inc
IPO dateAug 23, 2021
CEOHe (Wei-Wu)
Number of employees233
Security typeOrdinary Share
Fiscal year-endAug 23
Address1701-1702, China Central Office Tower 1
CityBEIJING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code100025
Phone861065618789
Websitehttps://www.casipharmaceuticals.com/
Ticker SymbolCASI
IPO dateAug 23, 2021
CEOHe (Wei-Wu)
Company Executives of CASI Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.75M
+5000000.00%
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alexander A. (Alex) Zukiwski, M.D.
Dr. Alexander A. (Alex) Zukiwski, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Wei (Larry) Zhang, Ph.D.
Mr. Wei (Larry) Zhang, Ph.D.
Senior Vice President
Senior Vice President
--
--
Mr. Zhenbo Su
Mr. Zhenbo Su
Independent Director
Independent Director
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Ms. Chunhua Wang
Ms. Chunhua Wang
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.75M
+5000000.00%
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alexander A. (Alex) Zukiwski, M.D.
Dr. Alexander A. (Alex) Zukiwski, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Wei (Larry) Zhang, Ph.D.
Mr. Wei (Larry) Zhang, Ph.D.
Senior Vice President
Senior Vice President
--
--
Mr. Zhenbo Su
Mr. Zhenbo Su
Independent Director
Independent Director
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 5
Updated: Thu, Feb 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
He (Wei-Wu)
42.56%
Panacea Venture
22.05%
Chen (Zhenfeng)
10.98%
Sparkle Byte Ltd
4.96%
VR Adviser, LLC
4.80%
Other
14.65%
Shareholders
Shareholders
Proportion
He (Wei-Wu)
42.56%
Panacea Venture
22.05%
Chen (Zhenfeng)
10.98%
Sparkle Byte Ltd
4.96%
VR Adviser, LLC
4.80%
Other
14.65%
Shareholder Types
Shareholders
Proportion
Individual Investor
53.55%
Venture Capital
31.31%
Corporation
9.39%
Private Equity
4.77%
Research Firm
1.40%
Hedge Fund
1.18%
Investment Advisor
0.39%
Investment Advisor/Hedge Fund
0.09%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
45
3.52M
15.33%
--
2025Q3
47
3.52M
15.49%
+359.82K
2025Q2
48
3.16M
23.83%
-498.95K
2025Q1
50
3.66M
24.24%
-92.72K
2024Q4
51
3.58M
28.44%
+88.23K
2024Q3
51
3.49M
21.30%
+239.12K
2024Q2
56
2.52M
16.64%
+1.41M
2024Q1
70
1.11M
17.01%
-1.17M
2023Q4
74
1.13M
12.84%
-66.87K
2023Q3
88
1.20M
16.17%
-105.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
He (Wei-Wu)
3.75M
18.23%
+230.00K
+6.54%
Dec 18, 2025
Panacea Venture
4.53M
22.05%
+979.96K
+27.60%
Dec 17, 2025
Chen (Zhenfeng)
2.26M
10.98%
+2.26M
--
Sep 30, 2025
Sparkle Byte Ltd
1.02M
4.96%
--
--
Mar 21, 2025
VR Adviser, LLC
987.26K
4.8%
--
--
Sep 30, 2025
Foresite Capital Management, LLC
979.96K
4.77%
+192.84K
+24.50%
Sep 30, 2025
IDG Capital Partners
915.85K
4.46%
+61.97K
+7.26%
Dec 30, 2024
Wealth Strategy Holding Ltd
908.79K
4.42%
--
--
Mar 21, 2025
BofA Global Research (US)
254.88K
1.24%
+242.82K
+2013.29%
Sep 30, 2025
Woodline Partners LP
165.64K
0.81%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
